Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments

Gene Therapy

Volumn 4, Issue 11, 1997, Pages 1160-1166

  Coll, J L ^a   Mesnil, M ^b   Lefebvre, M F ^a   Lancon, A ^a   Favrot, M C ^a  

^a CENTRE LÉON BÉRARD   (France)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

DOTAP; Gene therapy; HSV tk; IL 2; Intraperitoneal cavity

Indexed keywords

FLUORESCENT DYE; GANCICLOVIR; INTERLEUKIN 2; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL JUNCTION; COLON CARCINOMA; CONTROLLED STUDY; DRUG SENSITIZATION; FEMALE; GENE THERAPY; HERPES SIMPLEX VIRUS; IMMUNOCOMPETENCE; IMMUNOSTIMULATION; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0030782641     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300516     Document Type: Article

References (16)

1. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89: 21-39.
2. Freeman SM et al. The bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
3. Elshami AA et al. Gap junctions play a role in the 'brystander effect' of the herpes simplex virus thymidine kinase/ganciclovir in vitro. Gene Therapy 1996; 3: 85-92.
4. Beck C et al. The thymidine kinase/ganciclovir-mediated 'suicide' effect is variable in different tumor cells. Hum Gene Ther 1995; 6: 1525-1530.
5. Yee D et al. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther 1996; 7: 1251-1257.
6. Elshami AA et al. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 7: 141-148.
7. Smythe WR et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994; 54: 2055-2059.
8. Hwang HC et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Resp Cell Molec Biol 1995; 13: 7-16.
9. Smythe WR et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 1994; 57: 1395-1401.
10. Caruso M et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996; 93: 11302-11306.
11. Caignard A, Martin MS, Michel MF, Martin F. Interaction between two cellular subpopulations of a rat colonic carcinoma when inoculated to the syngeneic host. Int J Cancer 1985; 36: 273-279.
12. Chaux P, Hammann A, Martin F, Martin M. Surface phenotype and functions of tumor-infiltrating dendritic cells: CD8 expression by a cell subpopulation. Eur J Immunol 1993; 23: 2517-2525.
13. Mesnil M et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-1835.
14. Culver KW et al. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
15. Patry Y, Douillard JY, Meflah K, Le Pendu J. Immunization against a rat colon carcinoma by sodium butyrate-treated cells but not by interleukin 2-secreting cells. Gastroenterology 1995; 109: 1555-1565.
16. Chen S-H et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92: 2577-2581.